魔法子弹
医学
免疫系统
炎症性肠病
免疫学
炎症
炎症性肠病
免疫疗法
生物信息学
生物
疾病
内科学
作者
Markus F. Neurath,Bruce E. Sands,Florian Rieder
出处
期刊:Gut
[BMJ]
日期:2024-07-17
卷期号:: gutjnl-332919
标识
DOI:10.1136/gutjnl-2024-332919
摘要
Despite significant advances in biologic and small molecule treatments and the emergence of combination therapies to treat inflammatory bowel diseases (IBD) a large unmet need remains to control intestinal inflammation. New approaches targeting several pathways simultaneously with a favorable safety profile and agents that trigger anti-inflammatory pathways to drive durable resolution of inflammation are needed. This article discusses novel cellular immunotherapies and immune cell depleting therapies in IBD, including CAR-T cell approaches, Tr1 and T regulatory (Treg) cells and cell depleting antibodies such as rosnilimab. These novel approaches have the potential to overcome current therapeutic limitations in the treatment of IBD.
科研通智能强力驱动
Strongly Powered by AbleSci AI